NasdaqCM:CTIC

Stock Analysis Report

Executive Summary

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.

Rewards

Earnings have grown 24.3% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of -35.4% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($51M)



Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Amgen

NasdaqGS:AMGN

Share Price & News

How has CTI BioPharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CTIC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-8.7%

CTIC

0.5%

US Biotechs

0.7%

US Market


1 Year Return

-40.2%

CTIC

14.8%

US Biotechs

18.2%

US Market

Return vs Industry: CTIC underperformed the US Biotechs industry which returned 14.8% over the past year.

Return vs Market: CTIC underperformed the US Market which returned 18.2% over the past year.


Shareholder returns

CTICIndustryMarket
7 Day-8.7%0.5%0.7%
30 Day16.7%8.0%1.5%
90 Day18.0%14.9%5.0%
1 Year-40.2%-40.2%15.8%14.8%20.8%18.2%
3 Year-81.5%-81.5%28.1%24.0%45.2%35.8%
5 Year-96.0%-96.0%8.9%3.8%71.6%52.7%

Price Volatility Vs. Market

How volatile is CTI BioPharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CTI BioPharma undervalued compared to its fair value and its price relative to the market?

1.61x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CTIC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CTIC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CTIC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CTIC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CTIC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CTIC is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (3.1x).


Next Steps

Future Growth

How is CTI BioPharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-35.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTIC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CTIC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CTIC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CTIC's revenue is expected to decline over the next 3 years (-127.2% per year).

High Growth Revenue: CTIC's revenue is forecast to decline over the next 3 years (-127.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CTIC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CTI BioPharma performed over the past 5 years?

24.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CTIC is currently unprofitable.

Growing Profit Margin: CTIC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CTIC is unprofitable, but has reduced losses over the past 5 years at a rate of 24.3% per year.

Accelerating Growth: Unable to compare CTIC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTIC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: CTIC has a negative Return on Equity (-118.33%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is CTI BioPharma's financial position?


Financial Position Analysis

Short Term Liabilities: CTIC's short term assets ($49.7M) exceed its short term liabilities ($27.9M).

Long Term Liabilities: CTIC's short term assets ($49.7M) exceed its long term liabilities ($4.5M).


Debt to Equity History and Analysis

Debt Level: CTIC's debt to equity ratio (40%) is considered satisfactory.

Reducing Debt: CTIC's debt to equity ratio has reduced from 84.4% to 40% over the past 5 years.


Balance Sheet

Inventory Level: CTIC has a low level of unsold assets or inventory.

Debt Coverage by Assets: CTIC's debt is covered by short term assets (assets are 4.7x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CTIC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CTIC has sufficient cash runway for 1.372093 years if free cash flow continues to grow at historical rates of 29.2% each year.


Next Steps

Dividend

What is CTI BioPharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CTIC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CTIC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTIC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTIC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTIC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of CTI BioPharma's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average management tenure


CEO

Adam Craig (53yo)

2.8yrs

Tenure

US$3,032,655

Compensation

Dr. Adam R. Craig, M.D., Ph.D., M.B.A., has been the Chief Executive Officer, President and Director of CTI BioPharma Corp. since March 20, 2017 and serves its Interim Chief Medical Officer. Dr. Craig serv ...


CEO Compensation Analysis

Compensation vs Market: Adam's total compensation ($USD3.03M) is above average for companies of similar size in the US market ($USD502.49K).

Compensation vs Earnings: Adam's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.5yrs

Average Tenure

60yo

Average Age

Experienced Management: CTIC's management team is considered experienced (2.5 years average tenure).


Board Age and Tenure

2.9yrs

Average Tenure

55yo

Average Age

Experienced Board: CTIC's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.8%.


Management Team

  • Bruce Bennett (67yo)

    Senior Vice President Global Pharmaceutical Operations

    • Tenure: 0yrs
  • Adam Craig (53yo)

    President

    • Tenure: 2.8yrs
    • Compensation: US$3.03m
  • David Kirske (65yo)

    Executive VP

    • Tenure: 2.3yrs
    • Compensation: US$883.73k
  • Ed Bell

    Senior Director of Investor Relations

    • Tenure: 11.5yrs
  • Jim Fong

    Senior Vice President of US Commercial Operations

    • Tenure: 0yrs
  • Bruce Seeley (55yo)

    Executive VP & COO

    • Tenure: 2.3yrs
    • Compensation: US$1.13m

Board Members

  • Dan Von Hoff (71yo)

    Chairman of Scientific Advisory Board

    • Tenure: 6.4yrs
  • Laurent Fischer (55yo)

    Chairman of the Board

    • Tenure: 2.3yrs
    • Compensation: US$276.10k
  • David Parkinson (69yo)

    Independent Director

    • Tenure: 2.5yrs
    • Compensation: US$245.35k
  • Adam Craig (53yo)

    President

    • Tenure: 2.8yrs
    • Compensation: US$3.03m
  • Matthew Perry (46yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$239.10k
  • Reed Tuckson (68yo)

    Independent Director

    • Tenure: 8.3yrs
    • Compensation: US$252.60k
  • Michael Metzger (48yo)

    Independent Director

    • Tenure: 2.9yrs
    • Compensation: US$245.47k

Company Information

CTI BioPharma Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CTI BioPharma Corp.
  • Ticker: CTIC
  • Exchange: NasdaqCM
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$51.300m
  • Shares outstanding: 57.97m
  • Website: https://www.ctibiopharma.com

Number of Employees


Location

  • CTI BioPharma Corp.
  • 3101 Western Avenue
  • Suite 800
  • Seattle
  • Washington
  • 98121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CEPSDB (Deutsche Boerse AG)COM NPV(POST REV SPLIT)DEEURNo data
CTICNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 1997
0RLBLSE (London Stock Exchange)YesCommon StockGBEURMar 1997
CEPSDB (Deutsche Boerse AG)YesCommon StockDEEURMar 1997

Biography

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and international ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/09 23:54
End of Day Share Price2019/12/09 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.